Histogen Stock Performance
| HSTO Stock | USD 0.02 0.01 25.65% |
The company retains a Market Volatility (i.e., Beta) of -1.23, which attests to a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Histogen are expected to decrease by larger amounts. On the other hand, during market turmoil, Histogen is expected to outperform it. At this point, Histogen has a negative expected return of -1.49%. Please make sure to check out Histogen's treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Histogen performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Histogen has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Last Split Factor 1:20 | Dividend Date 2020-05-27 | Last Split Date 2022-06-03 |
| Begin Period Cash Flow | 15 M |
Histogen |
Histogen Relative Risk vs. Return Landscape
If you would invest 22.00 in Histogen on August 28, 2024 and sell it today you would lose (20.00) from holding Histogen or give up 90.91% of portfolio value over 90 days. Histogen is currently does not generate positive expected returns and assumes 13.4826% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Histogen, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Histogen Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Histogen's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Histogen, and traders can use it to determine the average amount a Histogen's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1106
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | HSTO |
Estimated Market Risk
| 13.48 actual daily | 96 96% of assets are less volatile |
Expected Return
| -1.49 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Histogen is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Histogen by adding Histogen to a well-diversified portfolio.
Histogen Fundamentals Growth
Histogen Stock prices reflect investors' perceptions of the future prospects and financial health of Histogen, and Histogen fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Histogen Stock performance.
| Return On Equity | -1.2 | ||||
| Return On Asset | -0.54 | ||||
| Operating Margin | (705.00) % | ||||
| Current Valuation | (4.49 M) | ||||
| Shares Outstanding | 4.27 M | ||||
| Price To Book | 0.02 X | ||||
| Price To Sales | 4.50 X | ||||
| Revenue | 19 K | ||||
| Gross Profit | (1.25 M) | ||||
| EBITDA | (11.92 M) | ||||
| Net Income | (12.38 M) | ||||
| Cash And Equivalents | 12.6 M | ||||
| Cash Per Share | 5.04 X | ||||
| Total Debt | 4.63 M | ||||
| Debt To Equity | 0.31 % | ||||
| Current Ratio | 13.22 X | ||||
| Book Value Per Share | 1.27 X | ||||
| Cash Flow From Operations | (10.07 M) | ||||
| Earnings Per Share | (2.81) X | ||||
| Market Capitalization | 85.44 K | ||||
| Total Asset | 19.07 M | ||||
| Retained Earnings | (88.27 M) | ||||
| Working Capital | 12.22 M | ||||
About Histogen Performance
By examining Histogen's fundamental ratios, stakeholders can obtain critical insights into Histogen's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Histogen is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 2.6 K | 2.7 K | |
| Return On Tangible Assets | (0.64) | (0.67) | |
| Return On Capital Employed | (0.69) | (0.72) | |
| Return On Assets | (0.64) | (0.67) | |
| Return On Equity | (0.85) | (0.89) |
Things to note about Histogen performance evaluation
Checking the ongoing alerts about Histogen for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Histogen help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Histogen generated a negative expected return over the last 90 days | |
| Histogen has high historical volatility and very poor performance | |
| Histogen has some characteristics of a very speculative penny stock | |
| Histogen has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 19 K. Net Loss for the year was (12.38 M) with loss before overhead, payroll, taxes, and interest of (1.25 M). | |
| Histogen currently holds about 12.6 M in cash with (10.07 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.04, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Histogen has a frail financial position based on the latest SEC disclosures |
- Analyzing Histogen's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Histogen's stock is overvalued or undervalued compared to its peers.
- Examining Histogen's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Histogen's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Histogen's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Histogen's stock. These opinions can provide insight into Histogen's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Histogen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Histogen Stock, please use our How to Invest in Histogen guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Histogen. If investors know Histogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Histogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.81) | Revenue Per Share 0.004 | Return On Assets (0.54) | Return On Equity (1.20) |
The market value of Histogen is measured differently than its book value, which is the value of Histogen that is recorded on the company's balance sheet. Investors also form their own opinion of Histogen's value that differs from its market value or its book value, called intrinsic value, which is Histogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Histogen's market value can be influenced by many factors that don't directly affect Histogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Histogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Histogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Histogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.